Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    Bioflavonoid Tangeretin regulates RANK/RANKL/OPG Signaling Proteins via Stimulating Estrogenic Activity in Ovariectomized Rats

    Weike Tian1, Wei Zhang2, Li Chen3, Junlei Liao1, Xuesong Yang1 Corresponding author

    1. 1Health Management Center, Affiliated Hospital of North Sichuan Medical College, Nanchong City, Sichuan Province, CHINA.
    2. 2Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, Nanchong City, Sichuan Province, CHINA.
    3. 3Department of Hospital Infection Management, Affiliated Hospital of North Sichuan Medical College, Nanchong City, Sichuan Province, CHINA.

    CORRESPONDENCE

    Xuesong Yang

    Health Management Center, Affiliated Hospital of North Sichuan Medical College, Nanchong City, Sichuan Province, CHINA.

    q63963462@outlook.com

    Received: 18-07-2024; Accepted: 14-10-2024.

    Volume 21, Issue 3 · pp. 1001–1012 · PUBLISHED 2025 · DOI: 10.1177/09731296241296201

    View on Pharmacogn. Mag. original site ↗

    ABSTRACT

    Background: Globally, osteoporosis has arisen as a significant health hazard, impacting over 200 million individuals. It is often reported in women, especially those who are in the postmenopausal stage. Even though numerous reasons are linked with osteoporosis etiology, estrogen deprivation is the prime inducer of osteoporosis. Objectives: The present research was intended to detect the bioflavonoid tangeretin potency against ameliorating osteoporosis in ovariectomized rats. Materials and Methods: Ovariectomy was performed in healthy female Sprague rats and treated with two different doses of the drug tangeretin. The body weight gain obtained by the experimental animals was noted throughout the experimental period. The uterus and vagina, the organ responsible for estrogen production and activity, were measured. Bone mineral density (BMD) and biomechanical properties of the femur were evaluated to study the impact of tangeretin. Bone biomarkers estradiol, bone GLA protein, and acid phosphatase were quantified to assess the impact of tangeretin on bone turnover. Serum phosphorous, calcium, creatinine, and tartrate-resistant acid phosphatase (TRAP), which are the osteoporosis risk factors, were analyzed in tangeretin-treated ovariectomized rats. Signaling proteins involved in the receptor activator of nuclear factor-κB (RANK)/receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) pathway, which is responsible for bone turnover, were quantified. Results: Tangeretin treatment significantly inhibited excess weight gain and increased the uterus and vaginal weight. BMD and biomechanical analysis of the femur prove tangeretin treatment increased the BMD and upgraded the biomechanical properties in ovariectomized animals. Tangeretin increased the estradiol and decreased the bone GLA protein and acid phosphatase. It also increased serum phosphorous, calcium, and creatinine and decreased the TRAP levels, confirming its ameliorative potency against bone turnover. It inhibited RANKL protein and increased the levels of OPG and its signaling molecules in ovariectomized rats. The anti-inflammatory bioflavonoid tangeretin attenuated the inflammatory stimulating cytokines in ovariectomized rats. Conclusion: Overall, our analysis confirms tangeretin possesses antiosteoporotic potency which effectively elevates estradiol and attenuates the bone turnover signaling pathway RANK/RANKL/OPG proteins in ovariectomized rats. The results of our research prove the establishment of a treatment strategy using tangeretin can improve bone health and prevent osteoporosis in menopausal women.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Tian, W., Zhang, W., Chen, L., Liao, J., & Yang, X. (2025). Bioflavonoid Tangeretin regulates RANK/RANKL/OPG Signaling Proteins via Stimulating Estrogenic Activity in Ovariectomized Rats. Pharmacognosy Magazine, 21(3), 1001–1012. https://doi.org/10.1177/09731296241296201